Maureen M. Jonas
YOU?
Author Swipe
View article: Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection
Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection Open
Background The safety and efficacy of sofosbuvir–velpatasvir in children aged 3–17 years with chronic hepatitis C virus (HCV) infection of any genotype were evaluated. Methods In this Phase 2, multicenter, open‐label study, patients receiv…
View article: ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings
ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings Open
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with more than three million viraemic adolescents and children. Treatment of adults with HCV infection and HCV‐related liver disease has advanced consid…
View article: Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study Open
Background: Approximately 3.5 million children and adolescents worldwide are chronically infected with HCV. This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentr…
View article: P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION
P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION Open
View article: Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study
Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study Open
Background and Aims Recurrent primary sclerosing cholangitis (rPSC) following liver transplant (LT) has a negative impact on graft and patient survival; little is known about risk factors for rPSC or disease course in children. Approach an…
View article: 一般演題（口演）
一般演題（口演） Open
57 回 日本肝臓学会総会 口演 肝臓 62 巻 suppl.(1)(2021)第 57 回 日本肝臓学会総会 口演 A285 O-3 Sonic hedgehog 免疫染色の風船状腫大 を示す肝細胞の検出における有用性 ○草野弘宣久留米大学病院臨床検査部 3 【目的】 非アルコール性脂肪肝炎 (NASH) では Hedgehog signaling pathway の活性化が見られることが知 られている．また免疫組織学的にも Sonic Hedgehog (SHh)が風船…
View article: Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study Open
Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV‐infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2/3, nonrandomized, open‐label study evaluating…
View article: Graves’ disease in a five-month-old boy with an unusual treatment course
Graves’ disease in a five-month-old boy with an unusual treatment course Open
Objectives Graves’ disease (GD) is rare in children under age five years. Antithyroid drugs are typically first-line therapy but carry the risks of agranulocytosis and liver dysfunction. Case presentation A male infant with multiple congen…
View article: IDDF2020-ABS-0059 Safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) in pediatric patients 6 to < 18 years old with chronic hepatitis C (CHC) infection
IDDF2020-ABS-0059 Safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) in pediatric patients 6 to < 18 years old with chronic hepatitis C (CHC) infection Open
Background DAA regimens have been approved for CHC treatment in 12 to Methods Patients 6 to Results 102 patients 12 to 15%) were headache, fatigue, and nausea in adolescents and vomiting, cough and headache in 6 to Conclusions In patients …
View article: Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis
Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis Open
Background and Aims Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. Approach and Result…
View article: The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children
The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children Open
Background and Aims Disease progression in children with primary sclerosing cholangitis (PSC) is variable. Prognostic and risk‐stratification tools exist for adult‐onset PSC, but not for children. We aimed to create a tool that accounts fo…
View article: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a Open
View article: Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat? Open
One of the most significant consequences of the opioid epidemic is the increased prevalence of hepatitis C virus (HCV) among pregnant women, which carries the risk of perinatal transmission.This increased prevalence of HCV in pregnant wome…
View article: Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant
Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant Open
Liver diseases affecting the mother and infant dyad may present in the perinatal period from 20 weeks of gestation to 28 days of life. This review will focus on the current approach to neonatal acute liver failure and the progress made in …
View article: Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3‒11 Years with Hepatitis C Genotype 1a
Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3‒11 Years with Hepatitis C Genotype 1a Open
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The…
View article: Esophageal Capsule Endoscopy in Children and Young Adults With Portal Hypertension
Esophageal Capsule Endoscopy in Children and Young Adults With Portal Hypertension Open
Objectives: Variceal hemorrhage (VH) is a serious complication of portal hypertension (PH). We evaluated the feasibility, safety, and clinical impact of esophageal capsule endoscopy (ECE) in pediatric and young adult patients with known or…
View article: Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study Open
The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatri…
View article: Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection Open
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open‐label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in ch…
View article: Hepatitis B virus infection in children and adolescents
Hepatitis B virus infection in children and adolescents Open
View article: Effect of Universal Infant Hepatitis B Virus Immunization on Mother-to-Child Hepatitis B Virus Transmission
Effect of Universal Infant Hepatitis B Virus Immunization on Mother-to-Child Hepatitis B Virus Transmission Open
View article: Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis
Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis Open
View article: Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia
Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia Open
Objective: The aim of the study was to evaluate the hepatotoxicity of statins, as determined by serum alanine aminotransferase (ALT), in children and adolescents with dyslipidemia in real‐world clinical practice. Study design: Clinical and…
View article: Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4 Open
In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR). However, the…
View article: Reply
Reply Open
Peer Reviewed
View article: Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection Open
Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed …
Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now Open
View article: Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance Open
In February 2018, the American Association for the Study of Liver Diseases (AASLD) published an update to the practice guideline on the prevention, diagnosis, and treatment of chronic hepatitis B (CHB). In contrast with the prior version, …
View article: Validation of Transient Elastography Cut Points to Assess Advanced Liver Fibrosis in Children and Young Adults: The Boston Children's Hospital Experience
Validation of Transient Elastography Cut Points to Assess Advanced Liver Fibrosis in Children and Young Adults: The Boston Children's Hospital Experience Open
View article: Health Related Quality of Life and Neurocognitive Outcomes in the First Year after Pediatric Acute Liver Failure
Health Related Quality of Life and Neurocognitive Outcomes in the First Year after Pediatric Acute Liver Failure Open
View article: Update on prevention, diagnosis, and treatment of chronic hepatitis B
Update on prevention, diagnosis, and treatment of chronic hepatitis B Open
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jonas consults for Gilead and received grants from Bristol‐Myers …